Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Protalix Biotherapeutics stock

PLX
US74365A3095
A2PWSL

Price

1.82
Today +/-
+0.02
Today %
+0.96 %

Protalix Biotherapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Protalix Biotherapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Protalix Biotherapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Protalix Biotherapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Protalix Biotherapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Protalix Biotherapeutics Stock Price History

DateProtalix Biotherapeutics Price
12/12/20241.82 undefined
12/11/20241.80 undefined
12/10/20241.83 undefined
12/9/20241.76 undefined
12/6/20241.69 undefined
12/5/20241.63 undefined
12/4/20241.63 undefined
12/3/20241.64 undefined
12/2/20241.67 undefined
11/29/20241.72 undefined
11/27/20241.69 undefined
11/26/20241.68 undefined
11/25/20241.71 undefined
11/22/20241.69 undefined
11/21/20241.66 undefined
11/20/20241.69 undefined
11/19/20241.63 undefined
11/18/20241.66 undefined
11/15/20241.40 undefined
11/14/20241.41 undefined
11/13/20241.26 undefined

Protalix Biotherapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Protalix Biotherapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Protalix Biotherapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Protalix Biotherapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Protalix Biotherapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Protalix Biotherapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Protalix Biotherapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Protalix Biotherapeutics’s growth potential.

Protalix Biotherapeutics Revenue, EBIT and net profit per share

DateProtalix Biotherapeutics RevenueProtalix Biotherapeutics EBITProtalix Biotherapeutics Net Income
2026e168.9 M undefined106.6 M undefined84.03 M undefined
2025e102.45 M undefined56.15 M undefined46.11 M undefined
2024e54.22 M undefined2.21 M undefined1.49 M undefined
202365.49 M undefined10.46 M undefined8.31 M undefined
202247.64 M undefined-13.01 M undefined-14.93 M undefined
202138.35 M undefined-20.46 M undefined-27.58 M undefined
202062.9 M undefined2.71 M undefined-6.52 M undefined
201954.69 M undefined-10.72 M undefined-18.28 M undefined
201834.24 M undefined-19.31 M undefined-26.46 M undefined
201721.08 M undefined-34.51 M undefined-83.44 M undefined
20169.2 M undefined-33.16 M undefined-29.37 M undefined
20154.36 M undefined-23.67 M undefined58.04 M undefined
20143.52 M undefined-28.56 M undefined-29.94 M undefined
20130 undefined-34.06 M undefined-27.79 M undefined
201234.42 M undefined-12.17 M undefined-11.62 M undefined
20112.97 M undefined-36.53 M undefined-36.53 M undefined
201011.24 M undefined-37.71 M undefined-36.74 M undefined
2009390,000 undefined-31.97 M undefined-31.44 M undefined
20080 undefined-24.17 M undefined-22.41 M undefined
20070 undefined-34.16 M undefined-32.08 M undefined
20060 undefined-9.77 M undefined-9.39 M undefined
2005150,000 undefined-5.79 M undefined-5.75 M undefined
2004430,000 undefined-2.42 M undefined-2.42 M undefined

Protalix Biotherapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
008300000000001123403492134546238476554102168
----62.50------------81.821,600.00--33.33125.00133.3361.9058.8214.81-38.7123.6838.30-16.9288.8964.71
--62.5066.67----------54.5550.0076.47-66.6775.00466.6723.8170.5979.6383.8757.8959.5764.6277.7841.1825.00
0052000000000-3612602305244352222842000
00-1-10000-2-5-9-32-22-31-36-36-11-27-2958-29-83-26-18-6-27-14814684
---------150.0080.00255.56-31.2540.9116.13--69.44145.457.41-300.00-150.00186.21-68.67-30.77-66.67350.00-48.15-157.14-87.504,500.0082.61
0.020.010.050.050.040.030.030.031.881.882.936.727.597.698.18.469.089.249.299.4910.1413.1114.7114.8429.1544.1448.4782.42000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Protalix Biotherapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Protalix Biotherapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
0.80.11.31.51.60.90.80.70.64.715.461.842.681.335.928.354.486.8567764.351.43817.818.33917.123.63
001.10000000.3000071.41.42.1000.71.74.74.723.44.65.27
000000000000001.70000000000000
000000000000001.20.3483.55.85.27.88.68.213.11816.819.05
6.600.20.20.2000007.60.30.40.40.62.51.31.16.13.11.61.71.71.822.31.36.421.98
7.40.12.61.71.80.90.80.70.652362.14381.746.432.561.19865.685.971.862.65332.555.761.744.969.93
000.800000022.44.56.814.517.518.316.313.711.39.78.77.76.41110.49.99.610.88
0000000000000000000000000000
010030030001000000000000000000000000
0000000000000000000000000000
0000000000000000000000000000
0010.20.100000.20.30.50.60.70.911.21.71.61.61.71.91.821.82.11.33.62
00.12.10.50.10.10002.22.757.415.218.419.317.515.412.911.310.49.68.21312.21210.914.5
7.40.24.72.21.910.80.70.67.225.767.150.496.964.851.878.6113.478.597.282.272.261.245.567.973.755.884.43
                                                       
000000000010010010010010010010010010010010010010000010073
005.64.54.34.24.24.24.217.244.7116.2119.3122.3124145.8180.1184.3185.6194.1202.6266.5269.5270.5320.3368.9379.2415.05
0-0.7-1.9-2.9-3-3.3-3.4-3.6-3.7-11.1-20.5-52.6-75-106.5-135.4-172-183.6-211.4-241.3-183.3-212.7-296.1-322.6-340.8-347.4-374.9-389.9-381.55
00-0.4-0.1000000000000000000000000
0000000000000000000000000000
0-0.73.31.51.30.90.80.60.56.124.363.744.415.9-11.3-26.1-3.4-27-55.610.9-10-29.5-53-70.3-27.1-6-10.633.57
00.11.20.30.50.10000.40.90.92.23.46.37.89.611.23.83.647.55.26.57.275.94.32
0000000.10.10.101.11.81.74.73.23.43.84.25.33.65.36.8810.41315.511.112.37
0.100.20.10.100000.40.311.613.59.47.412.511.455.243.12.512.118.97.710.715.58.59
00.50000000000000000000004.34.1000
0000.1000000000000000053.95.90054.40020.25
0.10.61.40.50.60.10.10.10.10.82.33.75.521.618.918.625.926.864.311.266.322.725.340.186.433.232.545.53
000000000000000006767.472.123.651.353.351.50.127.928.20
0000000000000000000000000000
7.30.300000000.30.40.70.961.357.159.256.346.52.332.327.635.424.18.418.65.85.34
7.30.300000000.30.40.70.961.357.159.256.3113.569.775.125.978.988.775.68.546.5345.34
7.40.91.40.50.60.10.10.10.11.12.74.46.482.97677.882.2140.313486.392.2101.6114115.794.979.766.550.87
7.40.24.721.910.90.70.67.22768.150.898.864.751.778.8113.378.497.282.272.16145.467.873.755.984.43
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Protalix Biotherapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Protalix Biotherapeutics's financial health and stability.

Assets

Protalix Biotherapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Protalix Biotherapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Protalix Biotherapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Protalix Biotherapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00-1-10000-2-5-9-32-22-31-29-36-11-27-2958-29-83-26-18-6-27-148
0000000000001133333211111111
000000000000000000000000000-3
00-1-100000001271-13703-2-372713-6-279-12-10
0010000001319652215-50-79-1144449822
0000000000000000003334444322
0000000000000000000000000000
000-10000-1-3-5-10-1644-38-230-30-29-24-32-9-7-19-26-10-25-1
00-300000-100-2-3-6-7-5-2-10000000-10-1
-60-300100-100-2-3-6-7-5-2-2-1390-100-1918-5-16
-6000010000000000000390000-1920-4-15
0000000000000000000000000000
000000000-10000000660019-1-400-3400
70000000281658000202600600004646824
705000003716580002026660619-1-404612824
0060000000000000000000000000
0000000000000000000000000000
00100000031046-1938-45-82534-3121-13-12-13-20020-216
-0.04-0.61-4.41-1.44-0.05-0.79-0.15-0.14-3.04-4.05-5.93-12.79-19.3938.25-46.32-29.28-1.43-32.54-30.07-24.74-32.95-10.96-8.43-19.99-26.77-11.75-25.63-2.47
0000000000000000000000000000

Protalix Biotherapeutics stock margins

The Protalix Biotherapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protalix Biotherapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protalix Biotherapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Protalix Biotherapeutics's sales revenue. A higher gross margin percentage indicates that the Protalix Biotherapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Protalix Biotherapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Protalix Biotherapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Protalix Biotherapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Protalix Biotherapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Protalix Biotherapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Protalix Biotherapeutics Margin History

Protalix Biotherapeutics Gross marginProtalix Biotherapeutics Profit marginProtalix Biotherapeutics EBIT marginProtalix Biotherapeutics Profit margin
2026e64.91 %63.11 %49.75 %
2025e64.91 %54.8 %45 %
2024e64.91 %4.07 %2.74 %
202364.91 %15.97 %12.69 %
202258.88 %-27.31 %-31.34 %
202157.37 %-53.35 %-71.92 %
202082.72 %4.31 %-10.37 %
201980.09 %-19.6 %-33.42 %
201872.84 %-56.4 %-77.28 %
201727.75 %-163.71 %-395.83 %
20168.7 %-360.43 %-319.24 %
201583.26 %-542.89 %1,331.19 %
201482.1 %-811.36 %-850.57 %
201364.91 %0 %0 %
201276.35 %-35.36 %-33.76 %
201148.48 %-1,229.97 %-1,229.97 %
201061.03 %-335.5 %-326.87 %
2009-817.95 %-8,197.44 %-8,061.54 %
200864.91 %0 %0 %
200764.91 %0 %0 %
200664.91 %0 %0 %
200580 %-3,860 %-3,833.33 %
200472.09 %-562.79 %-562.79 %

Protalix Biotherapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Protalix Biotherapeutics earnings per share therefore indicates how much revenue Protalix Biotherapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protalix Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protalix Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protalix Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protalix Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Protalix Biotherapeutics Revenue, EBIT and net profit per share

DateProtalix Biotherapeutics Sales per ShareProtalix Biotherapeutics EBIT per shareProtalix Biotherapeutics Earnings per Share
2026e2.29 undefined0 undefined1.14 undefined
2025e1.39 undefined0 undefined0.63 undefined
2024e0.74 undefined0 undefined0.02 undefined
20230.79 undefined0.13 undefined0.1 undefined
20220.98 undefined-0.27 undefined-0.31 undefined
20210.87 undefined-0.46 undefined-0.62 undefined
20202.16 undefined0.09 undefined-0.22 undefined
20193.69 undefined-0.72 undefined-1.23 undefined
20182.33 undefined-1.31 undefined-1.8 undefined
20171.61 undefined-2.63 undefined-6.36 undefined
20160.91 undefined-3.27 undefined-2.9 undefined
20150.46 undefined-2.49 undefined6.12 undefined
20140.38 undefined-3.07 undefined-3.22 undefined
20130 undefined-3.69 undefined-3.01 undefined
20123.79 undefined-1.34 undefined-1.28 undefined
20110.35 undefined-4.32 undefined-4.32 undefined
20101.39 undefined-4.66 undefined-4.54 undefined
20090.05 undefined-4.16 undefined-4.09 undefined
20080 undefined-3.18 undefined-2.95 undefined
20070 undefined-5.08 undefined-4.77 undefined
20060 undefined-3.33 undefined-3.2 undefined
20050.08 undefined-3.08 undefined-3.06 undefined
20040.23 undefined-1.29 undefined-1.29 undefined

Protalix Biotherapeutics business model

Protalix Biotherapeutics Inc is a biopharmaceutical company founded in 1993. Its headquarters is located in Karmiel, Israel. The company's main goal is to develop innovative drugs for the treatment of various diseases based on plant cell cultures. Protalix Biotherapeutics Inc's business model focuses on researching and developing drugs for diseases where there has been no cure. The company relies on an advanced technology platform that allows the use of plant cell cultures for the production of biopharmaceutical products. This method is not only cost-effective compared to other methods, but it also enables the production of drugs in larger quantities. Protalix Biotherapeutics Inc is divided into several divisions, including research, development, and manufacturing of drugs for lysosomal storage diseases, hematological and rheumatological diseases, as well as vascular anomalies and infectious diseases. Lysosomal storage diseases, for which Protalix Biotherapeutics Inc develops drugs, are inherited metabolic disorders. These diseases are rare and mostly occur in children. Affected individuals cannot produce or produce enzymes insufficiently, leading to an accumulation of waste products in the cells. These diseases are often severe and can lead to death if untreated. Examples of lysosomal storage diseases for which Protalix Biotherapeutics Inc develops drugs include Gaucher disease, Fabry syndrome, Pompe disease, and mucopolysaccharidosis type I. In the field of hematological and rheumatological diseases, Protalix Biotherapeutics Inc develops drugs for diseases such as hemophilia, rheumatoid arthritis, and Crohn's disease. Hemophilia is an inherited disease where blood clotting factor VIII or IX is missing or insufficiently produced. Rheumatoid arthritis is an inflammatory joint disease that often occurs in the elderly. Crohn's disease is a chronic inflammatory bowel disease that can lead to severe diarrhea. For the treatment of vascular anomalies, Protalix Biotherapeutics Inc is developing a drug called PRX-102. These diseases affect the body's vascular system and can cause dangerous bleeding. PRX-102 is a protein replacement therapy that replaces the body's production of the missing enzyme. In the field of infectious diseases, Protalix Biotherapeutics Inc is developing a drug called OPRX-106. This drug is an immunomodulator used to treat autoimmune diseases where the body's immune system attacks its own tissues. One of the main products offered by Protalix Biotherapeutics Inc is the drug Elelyso. This drug is used to treat Gaucher disease. Elelyso is the first drug approved by the US Food and Drug Administration (FDA) based on plant cell cultures. The drug is available in the US, Israel, and Brazil. Another important product of Protalix Biotherapeutics Inc is the drug PRX-102. This drug is still in the clinical development phase. PRX-102 is used to treat Fabry syndrome and is a protein replacement therapy that replaces the body's production of the missing enzyme. Overall, Protalix Biotherapeutics Inc is an innovative biopharmaceutical company specializing in the development of drugs for rare and serious diseases. The advanced technology platform based on plant cell cultures allows for effective and cost-efficient production of biopharmaceutical products. The company's different divisions allow it to cater specifically to the needs of patients with lysosomal storage diseases, hematological and rheumatological diseases, as well as vascular anomalies and infectious diseases. Protalix Biotherapeutics is one of the most popular companies on Eulerpool.com.

Protalix Biotherapeutics SWOT Analysis

Strengths

Protalix Biotherapeutics Inc. has several strengths that contribute to its competitive advantage:

  • Advanced technology and expertise in protein expression and development of therapeutic enzymes.
  • Strong research and development capabilities, enabling the company to innovate and develop novel drug candidates.
  • Successful track record of partnerships and collaborations with pharmaceutical industry leaders.
  • Highly experienced and skilled management team with deep knowledge of the biopharmaceutical industry.

Weaknesses

Despite its strengths, Protalix Biotherapeutics Inc. faces some weaknesses that need to be addressed:

  • Reliance on few key products, which exposes the company to potential revenue fluctuations.
  • Limited marketing and commercialization capabilities, resulting in challenges in reaching a wider customer base.
  • Significant research and development expenses that may impact profitability in the short term.

Opportunities

Protalix Biotherapeutics Inc. has the following opportunities for growth:

  • Expanding product pipeline by developing new therapeutic enzyme candidates to address unmet medical needs.
  • Increasing demand for biopharmaceuticals globally, presenting a growing market to tap into.
  • Potential partnerships with academic institutions or biotechnology companies to access new technologies or intellectual property.
  • Exploring international markets and expanding distribution networks to reach a broader customer base.

Threats

Protalix Biotherapeutics Inc. faces certain threats that may hinder its growth and success:

  • Intense competition from other biopharmaceutical companies, both established and emerging.
  • Stringent regulatory requirements and approval processes for drug candidates, leading to potential delays or obstacles.
  • Economic fluctuations and healthcare reforms that may impact pricing and reimbursement policies.
  • Potential legal and patent disputes related to intellectual property rights.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Protalix Biotherapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Protalix Biotherapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Protalix Biotherapeutics shares outstanding

The number of shares was Protalix Biotherapeutics in 2023 — This indicates how many shares 82.424 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protalix Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protalix Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protalix Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protalix Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Protalix Biotherapeutics stock splits

In Protalix Biotherapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Protalix Biotherapeutics.

Protalix Biotherapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.04 0.03  (-25.74 %)2024 Q3
6/30/20240.02 -0.03  (-248.51 %)2024 Q2
3/31/2024-0.02 -0.06  (-197.03 %)2024 Q1
12/31/2023-0.03 -0.07  (-131.02 %)2023 Q4
9/30/2023-0.07 -0.04  (43.42 %)2023 Q3
6/30/2023-0.04 0.21  (619.8 %)2023 Q2
3/31/20230 -0.05  (0 %)2023 Q1
12/31/2022-0.15 -0.07  (53.8 %)2022 Q4
9/30/2022-0.15 -0.07  (53.8 %)2022 Q3
6/30/2022-0.18 -0.11  (39.49 %)2022 Q2
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Protalix Biotherapeutics stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

75

👫 Social

73

🏛️ Governance

59

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Protalix Biotherapeutics shareholders

%
Name
Stocks
Change
Date
6.40062 % HIR Investments Ltd4,712,7732,313,5404/29/2024
3.40231 % Akirov (Alfred)2,505,1201,5064/29/2024
3.09919 % Bashan (Dror)2,281,9341,063,9604/29/2024
1.10167 % Millennium Management LLC811,160800,6766/30/2024
1.09276 % Renaissance Technologies LLC804,600-20,1006/30/2024
0.77414 % Rubin (Eyal)570,000201,9034/29/2024
0.58703 % Goldman Sachs & Company, Inc.432,231368,9836/30/2024
0.54495 % GSA Capital Partners LLP401,244-92,3276/30/2024
0.47361 % Northern Trust Investments, Inc.348,717-42,0656/30/2024
0.41252 % BlackRock Institutional Trust Company, N.A.303,740-2,682,4916/30/2024
1
2
3
4
5
...
10

Protalix Biotherapeutics Executives and Management Board

Mr. Dror Bashan

(56)
Protalix Biotherapeutics President, Chief Executive Officer, Director (since 2019)
Compensation 1.47 M

Mr. Eyal Rubin

(47)
Protalix Biotherapeutics Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Compensation 1.06 M

Mr. Yaron Naos

(59)
Protalix Biotherapeutics Senior Vice President - Operations
Compensation 533,265

Mr. Zeev Bronfeld

(72)
Protalix Biotherapeutics Independent Chairman of the Board
Compensation 94,022

Mr. Amos Bar Shalev

(70)
Protalix Biotherapeutics Independent Director
Compensation 61,464
1
2
3

Protalix Biotherapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Denka Stock
Denka
SupplierCustomer0,450,21-0,23-0,510,210,05
Pfizer Stock
Pfizer
SupplierCustomer0,130,790,68-0,18-0,70-0,81
1

Most common questions regarding Protalix Biotherapeutics

What values and corporate philosophy does Protalix Biotherapeutics represent?

Protalix Biotherapeutics Inc represents values of innovation, dedication, and patient-focused healthcare. The company believes in pushing boundaries to develop novel biologic therapies for challenging medical conditions. By harnessing its proprietary ProCellEx® plant cell-based protein expression system, Protalix aims to deliver high-quality, cost-effective treatments to patients worldwide. The company's corporate philosophy revolves around a commitment to scientific excellence, integrity, and improving the lives of individuals affected by rare diseases. Protalix Biotherapeutics Inc stands as a leading biopharmaceutical company dedicated to transforming the future of healthcare through breakthrough therapies and compassionate patient care.

In which countries and regions is Protalix Biotherapeutics primarily present?

Protalix Biotherapeutics Inc is primarily present in various countries and regions around the world. The company is actively engaged and has a strong presence in the United States and Israel, where its headquarters are located. Additionally, Protalix Biotherapeutics Inc has expanded its operations and partnerships to other countries, including Europe, Latin America, and Asia. Through strategic collaborations and distribution agreements, the company aims to provide its innovative biopharmaceutical solutions to patients globally. Protalix Biotherapeutics Inc's commitment to international expansion allows it to reach a wider audience and explore new markets for its cutting-edge therapies.

What significant milestones has the company Protalix Biotherapeutics achieved?

Protalix Biotherapeutics Inc has achieved several significant milestones. Firstly, the company received FDA approval for its drug, Elelyso, in 2012. Elelyso is an enzyme replacement therapy used for the treatment of Gaucher disease. Additionally, Protalix successfully developed and manufactured Taliglucerase alfa, a plant cell-expressed recombinant protein, becoming the first company to gain regulatory approval for a plant cell-based biopharmaceutical. In 2020, the company announced positive results from Phase III clinical trials for pegunigalsidase alfa, a potential therapy for Fabry disease. These achievements exemplify Protalix Biotherapeutics Inc's dedication to advancing biopharmaceuticals and improving patient outcomes. (Note: As an AI language model, I don't have real-time information and the mentioned achievements may not be up-to-date. It's always recommended to refer to the company's official sources for the most recent and accurate information.)

What is the history and background of the company Protalix Biotherapeutics?

Protalix Biotherapeutics Inc is a leading biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. Founded in 1993, Protalix has a rich history of innovation and breakthroughs in the field of biotechnology. The company has pioneered the use of plant cell-based expression system, ProCellEx®, to produce high-quality therapeutic proteins. This proprietary technology enables the efficient and cost-effective production of complex proteins with enhanced stability and bioactivity. Protalix has achieved significant milestones, including the first FDA-approved plant cell-based therapy, and continues to advance its diverse pipeline of potential treatments for various diseases. With a commitment to delivering groundbreaking therapies, Protalix Biotherapeutics Inc remains at the forefront of the biopharmaceutical industry.

Who are the main competitors of Protalix Biotherapeutics in the market?

The main competitors of Protalix Biotherapeutics Inc in the market are Genzyme Corporation, Shire plc, and Pfizer Inc.

In which industries is Protalix Biotherapeutics primarily active?

Protalix Biotherapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Protalix Biotherapeutics?

The business model of Protalix Biotherapeutics Inc revolves around developing and commercializing innovative recombinant protein therapeutics. As a biopharmaceutical company, Protalix utilizes its proprietary plant cell-based protein expression system, ProCellEx®, to produce therapeutic proteins. This advanced technology enables Protalix to produce biologic drugs with improved safety, efficacy, and cost-effectiveness compared to traditional methods. The company focuses on developing treatments for rare and orphan diseases, such as Fabry disease and Gaucher disease. By leveraging its unique plant-based platform, Protalix aims to address unmet medical needs and provide patients with access to life-changing therapies.

What is the P/E ratio of Protalix Biotherapeutics 2024?

The Protalix Biotherapeutics P/E ratio is 100.71.

What is the P/S ratio of Protalix Biotherapeutics 2024?

The Protalix Biotherapeutics P/S ratio is 2.76.

What is the Quality Investing of Protalix Biotherapeutics?

The Quality Investing for Protalix Biotherapeutics is 4/10.

What is the revenue of Protalix Biotherapeutics 2024?

The expected Protalix Biotherapeutics revenue is 54.22 M USD.

How high is the profit of Protalix Biotherapeutics 2024?

The expected Protalix Biotherapeutics profit is 1.49 M USD.

What is the business model of Protalix Biotherapeutics

Protalix Biotherapeutics Inc is a leading company in the field of biotechnology and biopharmaceuticals. The company specializes in the development and production of therapeutics based on enzymes and is an important player in the industry. The company's business model is based on the development, production, and marketing of biological products for the treatment of rare diseases, with a focus on the production of therapeutic enzymes for the treatment of lysosomal storage diseases. Protalix Biotherapeutics Inc has proven to be a leader in research and development in recent years, with an extensive pipeline of potential biological products. Its core product is Elelyso, a recombinant human glucocerebrosidase enzyme used in the treatment of Gaucher disease type 1. In addition to Elelyso, the company has developed a variety of pipeline products and patented protein expression technology that has the potential to enable faster and more efficient production of biological products. It also has research and development agreements with other biopharmaceutical companies and cooperative agreements with research institutions. Overall, Protalix Biotherapeutics Inc is well-positioned to continue growing and expanding its leading position in the industry.

What is the Protalix Biotherapeutics dividend?

Protalix Biotherapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Protalix Biotherapeutics pay dividends?

The dividend cannot currently be calculated for Protalix Biotherapeutics or the company does not pay out a dividend.

What is the Protalix Biotherapeutics ISIN?

The ISIN of Protalix Biotherapeutics is US74365A3095.

What is the Protalix Biotherapeutics WKN?

The WKN of Protalix Biotherapeutics is A2PWSL.

What is the Protalix Biotherapeutics ticker?

The ticker of Protalix Biotherapeutics is PLX.

How much dividend does Protalix Biotherapeutics pay?

Over the past 12 months, Protalix Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protalix Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protalix Biotherapeutics?

The current dividend yield of Protalix Biotherapeutics is .

When does Protalix Biotherapeutics pay dividends?

Protalix Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protalix Biotherapeutics?

Protalix Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Protalix Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protalix Biotherapeutics located?

Protalix Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protalix Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protalix Biotherapeutics from 12/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did Protalix Biotherapeutics pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of Protalix Biotherapeutics in the year 2023?

In the year 2023, Protalix Biotherapeutics distributed 0 USD as dividends.

In which currency does Protalix Biotherapeutics pay out the dividend?

The dividends of Protalix Biotherapeutics are distributed in USD.

All fundamentals about Protalix Biotherapeutics

Our stock analysis for Protalix Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protalix Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.